Immunoglobulins: all 43 studies that test it
Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell LymphomaNot yet recruitingNCT07754682Phase 3
- A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)RecruitingNCT06752356Phase 3
- Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell ImpairmentRecruitingNCT06159283Phase 2
- Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)RecruitingNCT04589299Phase 4
- Randomised Evaluation of COVID-19 TherapyRecruitingNCT04381936Phase 3
- An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency DiseaseCompletedNCT04842643Phase 3Results posted
- A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)CompletedNCT04346108Phase 3Results posted
- A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT02549170Phase 3Results posted
- A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's DiseaseCompletedNCT01561053Phase 2/3Results posted
- Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)CompletedNCT01199705Phase 3Results posted
- Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00322556Phase 3Results posted
- Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10CompletedNCT00168038Phase 3Results posted
- An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)CompletedNCT07076446Phase 4
- Subcutaneous Immunoglobulin for Myasthenia GravisCompletedNCT04728425Phase 2
- Convalescent Antibodies Infusion in COVID 19 PatientsWithdrawnNCT04418531Not applicable
- Convalescent Antibodies Infusion in Critically Ill COVID 19 PatientsTerminatedNCT04346589Not applicable
- Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic SyndromeSuspendedNCT03560011Phase 2/3
- Human IgGs and Endothelial Function in Vivo in HumansCompletedNCT03534479Not applicable
- Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral ImmunodeficiencyWithdrawnNCT03492710Phase 3
- Subcutaneous Ig in Allogeneic Stem Cell Transplant RecipientsCompletedNCT03401268Not applicable
- Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous IgCompletedNCT03211065Phase 2/3
- Panzyga in CIDP Administered at Different Infusion RatesStatus unknownNCT03166527Phase 3
- The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy LossStatus unknownNCT02990403Phase 4
- Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly SchedulesCompletedNCT02711228Phase 4
- Immunotherapy and Paraneoplastic Neurological SyndromesCompletedNCT02343211Phase 2
- Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept StudyTerminatedNCT02271165Early Phase 1
- IVIG Treatment for Asthmatic Patients With IgG Subclass DeficiencyStatus unknownNCT01992328Phase 3
- Subcutaneous Ig Maintenance Therapy for Myasthenia GravisTerminatedNCT01828294Phase 1
- Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT01017159Phase 2
- Subcutaneous Immunoglobulin Treatment for Multifocal Motor NeuropathyCompletedNCT00268788Phase 2
- Intravenous Immune Globulin to Treat Hereditary Inclusion Body MyopathyCompletedNCT00195637Phase 1
- Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00168025Phase 3
- Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00168012Phase 3
- Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre SyndromeTerminatedNCT00004833Not applicable
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating PolyneuropathyCompletedNCT00004772Phase 3
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple SclerosisCompletedNCT00004744Phase 3
- Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia GravisTerminatedNCT00004682Not applicable
- Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis InfectionCompletedNCT00004422Phase 3
- Randomized Study of Intravenous Immunoglobulin (IVIg) in Patients With Subacute Proximal Diabetic NeuropathyTerminatedNCT00004407Not applicable
- Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating NeuropathyCompletedNCT00004286Phase 3
- Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)CompletedNCT00000590Phase 3
- Transfusion-Transmitted Cytomegalovirus Prevention in NeonatesCompletedNCT00000584Phase 3
- Intravenous Immunoglobulin Therapy in Optic NeuritisCompletedNCT00000117Phase 3